Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.53 |
| ▸ | VKORC1 | Q9BQB6 | 1/20 | 0.53 |
| ▸ | MGAM | O43451 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 4/20 | 0.52 |
| ▸ | SI | P14410 | 4/20 | 0.52 |
| ▸ | MGAM2 | Q2M2H8 | 4/20 | 0.52 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.44 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28369886 | 0.79 | VKORC1 (0.65) | PTPN1VKORC1MGAMGAASI | |
| SCHEMBL28552754 | 0.78 | VKORC1 (0.67) | PTPN1VKORC1MGAMGAASI | |
| SCHEMBL28444444 | 0.78 | VKORC1 (0.67) | PTPN1VKORC1MGAMGAASI | |
| SCHEMBL27006392 | 0.75 | PTPN1 (0.52) | PTPN1VKORC1MGAMGAASI | |
| SCHEMBL15361080 | 0.75 | CYP3A4 (0.65) | PTPN1MGAMGAASIMGAM2 | |
| SCHEMBL27971484 | 0.75 | VKORC1 (0.51) | PTPN1VKORC1MGAMGAASI | |
| SCHEMBL7047705 | 0.71 | CYP3A4 (0.59) | PTPN1VKORC1MGAMABCG2CYP19A1 | |
| SCHEMBL20954088 | 0.71 | DYRK1A (0.73) | PTPN1ABCG2MAOAPPARGPPARA | |
| SCHEMBL316143 | 0.70 | KDM4E (0.62) | GAAABCG2CYP19A1MAOACYP3A4 | |
| SCHEMBL20954093 | 0.70 | ABCG2 (0.82) | PTPN1MGAMGAASIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016777-A1 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016777-A1 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS | THPO, SERPINB1, SERPINC1 | PTPN1 1318/4885VKORC1 407/4885MGAM 2440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.